MetLife Investment Management LLC Cuts Stake in Humana Inc. (NYSE:HUM)

MetLife Investment Management LLC lessened its stake in Humana Inc. (NYSE:HUM) by 2.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,312 shares of the insurance provider’s stock after selling 830 shares during the quarter. MetLife Investment Management LLC’s holdings in Humana were worth $9,918,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of HUM. CreativeOne Wealth LLC purchased a new position in Humana in the third quarter worth about $208,000. Blueshift Asset Management LLC bought a new stake in shares of Humana during the third quarter valued at approximately $803,000. Glenmede Trust Co. NA raised its holdings in Humana by 7.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 25,718 shares of the insurance provider’s stock worth $8,146,000 after acquiring an additional 1,813 shares during the last quarter. Cynosure Group LLC lifted its position in Humana by 11.2% in the 3rd quarter. Cynosure Group LLC now owns 1,324 shares of the insurance provider’s stock valued at $419,000 after acquiring an additional 133 shares in the last quarter. Finally, Sanders Capital LLC boosted its stake in Humana by 1.0% during the 3rd quarter. Sanders Capital LLC now owns 1,168,341 shares of the insurance provider’s stock valued at $370,060,000 after purchasing an additional 11,923 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

HUM opened at $296.68 on Friday. The company has a 50 day simple moving average of $275.60 and a two-hundred day simple moving average of $329.77. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market cap of $35.72 billion, a P/E ratio of 26.28, a PEG ratio of 2.40 and a beta of 0.52. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $526.47.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Equities analysts forecast that Humana Inc. will post 15.86 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a yield of 1.19%. Humana’s dividend payout ratio is presently 31.36%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on HUM shares. Deutsche Bank Aktiengesellschaft dropped their price objective on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research report on Thursday, October 3rd. TD Cowen raised their price target on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Leerink Partners cut shares of Humana from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $400.00 to $250.00 in a report on Wednesday, October 2nd. Royal Bank of Canada dropped their target price on shares of Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Truist Financial decreased their target price on shares of Humana from $400.00 to $260.00 and set a “hold” rating for the company in a research note on Friday, October 11th. Twenty analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.